Table 3. Multivariate analysis of the ability of the BCT score and other prognostic models based on traditional clinicopathological parameters to predict DMFS in pN0-N1, HR+/HER2− breast cancer patients treated with hormone therapy alone.
| Discovery cohort |
Validation cohort |
|||||
|---|---|---|---|---|---|---|
| Hazard ratio | 95% CI | P value | Hazard ratio | 95% CI | P value | |
| BCT score | 4.86 | (1.87–12.68) | 0.001 | 1.59 | (1.12–2.25) | 0.009 |
| NPI Score | >100 | (0.00-Inf) | 0.997 | >100 | (0.00-Inf) | 0.998 |
| PREDICT | 1.01 | (0.87–1.18) | 0.869 | 0.91 | (0.77–1.09) | 0.318 |
| SNAP | 1.06 | (0.67–1.66) | 0.805 | 0.96 | (0.74–1.24) | 0.730 |
Abbreviations: CI, confidence interval; NPI, Nottingham Prognostic Index; PREDICT (www.predict.nhs.uk); SNAP (www.CancerMath.net). Hazard ratios with P values < 0.05 are marked in bold.